TB-500

Thymosin beta-4 is the main intracellular G-actin sequestering protein, and the seven-residue LKKTETQ motif is the region responsible for that binding. Freeing up actin monomers lets endothelial cells, keratinocytes and stem cells reorganise their cytoskeletons and migrate, which is why the effect shows up as faster wound closure and capillary ingrowth rather than as a local anabolic effect. Rodent and rabbit models also show reduced myofibroblast activity and less collagen scar after cardiac and dermal injury. An important labelling caveat: 'TB-500' is used loosely, and much of what is sold under that name is full-length synthetic thymosin beta-4 rather than the short fragment - check the certificate of analysis mass before assuming which one is in the vial.

Targets: G-actin, Cell migration machinery, Angiogenic signalling in endothelial cells, Myofibroblast / fibrosis pathways

• · Four to six weeks of loading is the near-universal anecdotal convention, giving 4-5 mg per week.
• · Run after loading for as long as the injury is still improving. Systemic subcutaneous dosing is standard - unlike BPC-157, there is no strong rationale for injecting near the injury.

Work out your exact syringe units →

• commonInjection-site redness or lump— Rotate sites; the weekly volumes are larger than with BPC-157.
• commonLethargy or 'heavy' feeling for a day after dosing— Very frequently reported during the loading phase and usually fades with maintenance dosing.
• uncommonHead rush or light-headedness shortly after injection
• uncommonFlu-like malaise— Reported at the higher end of loading doses.

• Active malignancy - thymosin beta-4 promotes cell migration and angiogenesis, and increased Tβ4 expression is associated with metastatic potential in several tumour types. This is the one genuinely serious theoretical risk of the compound.
• Tested athletes - TB-500 is explicitly named on the WADA prohibited list and is routinely detected.

• synergybpc-157 — The archetypal repair stack; complementary mechanisms rather than overlapping ones.
• redundantthymosin-beta-4 — Same biology, and often literally the same molecule depending on what the vendor actually shipped.
• synergyghk-cu — Combined where matrix quality matters, such as dermal wounds and post-surgical scar.

• · No established bloodwork.
• · If you have any personal or strong family history of cancer, this is the peptide in the class worth discussing with an oncologist before starting.
• · Track the injury with a fixed, repeatable loading test.

Not approved for human use anywhere; sold as a research chemical. Explicitly prohibited by WADA at all times. On 23 July 2026 the FDA's Pharmacy Compounding Advisory Committee voted 8-6 to recommend TB-500 for the 503A Bulks List; the vote is non-binding and the FDA has not adopted it.

• Goldstein, Hannappel & Kleinman, thymosin beta-4 in tissue repair and regeneration (review) (review)
• Bock-Marquette et al. 2004, thymosin beta-4 activates integrin-linked kinase and promotes cardiac repair, Nature (preclinical)
• FDA Pharmacy Compounding Advisory Committee, 23-24 July 2026 meeting materials (guideline)

Thymosin beta-4 is the principal intracellular G-actin sequestering protein in mammalian cells, present at genuinely enormous concentrations - hundreds of micromolar in some cell types. Its job is to hold a reservoir of unpolymerised actin monomers so a cell can rebuild its cytoskeleton on demand. The LKKTETQ motif is the part of the molecule responsible for that binding, which is why the fragment was marketed as the active piece. The mechanistic problem with that logic is that actin sequestration is an intracellular function, and an injected peptide is extracellular. The effects that actually matter therapeutically - endothelial migration, keratinocyte migration, progenitor recruitment, reduced fibrosis - are increasingly attributed to signalling that does not require the peptide to get inside a cell and grab actin. Bock-Marquette's Nature paper showed thymosin beta-4 activates integrin-linked kinase and Akt in cardiac cells, promoting survival and migration, and that ILK pathway is a plausible extracellular-triggered route. Clinically this is why the effect looks like faster closure and better vascularisation rather than a local anabolic effect. You do not get more tissue, you get the tissue you were going to build arriving faster and organised with less scar. The antifibrotic component may be partly the Ac-SDKP tetrapeptide released from the thymosin beta-4 N-terminus, which is a known inhibitor of fibroblast proliferation and collagen deposition in its own right. The reason loading phases exist is worth stating plainly: nothing much happens in week one. Whether that is a genuine tissue-accumulation phenomenon or simply how long the underlying repair takes has never been tested. The cancer concern is not hand-waving. Thymosin beta-4 overexpression correlates with invasiveness and metastatic potential across several tumour types, and the mechanism - unlocking cell migration and driving angiogenesis - is exactly what a metastasising cell needs. This is the one theoretical risk in this class that deserves to be taken literally.

The most common problem is not knowing what is in the vial. There is no standardised definition of TB-500. Some vendors ship the seven-residue LKKTETQ fragment, some ship full-length 43-residue thymosin beta-4 at 4963 Da, and some ship an acetylated variant. Those are different molecules with different mass, different cost of goods and probably different activity. Ask for the mass spectrum. The second is dosing without weighing the cancer question honestly. This is not a generic 'consult your doctor' caveat - the specific biology of thymosin beta-4 is elevated expression tracking with tumour invasiveness. If you have a personal history of malignancy or a strong family history, this is the one peptide in the class where an oncologist's view is worth actually getting before you start. The third is the loading-phase malaise being read as a sign the compound is working. The day-after lethargy and occasional flu-like feeling are extremely commonly reported and mean nothing about efficacy. They also fade, so people who quit in week two because they feel bad are quitting before the compound has had a chance to do anything. The fourth is site management. The weekly volumes are larger than with BPC-157 and lumps and redness are common. Rotate sites deliberately rather than injecting the same spot because it worked last time. And finally, WADA. TB-500 is explicitly named on the prohibited list, is prohibited at all times rather than in-competition only, and is routinely detected. If you are drug-tested, this is not a grey area.

1. 2.5 mgWeeks 1-4 (loading) — Twice weekly, so 5 mg per week total. Split across the week, for example Monday and Thursday. Expect the day-after lethargy that most people report - it is the most consistent subjective effect of the compound and it fades.
2. 2.5 mgWeeks 5-6 (extended loading, optional) — Twice weekly continued to six weeks if the injury is large or chronic. Beyond six weeks of loading there is no rationale at all, anecdotal or otherwise.
3. 2.5 mgWeeks 7-14 (maintenance) — Once weekly, same day each week, for as long as the injury is still measurably improving. Systemic subcutaneous dosing is standard - unlike BPC-157 there is no rationale for injecting near the injury, because the mechanism is not local.
4. —After week 14 — Stop. There is no long-term safety data, and the theoretical cancer concern is a reason not to run this continuously the way people run BPC-157.

• G-actin (monomeric actin) — Full-length thymosin beta-4 binds G-actin with a dissociation constant in the low micromolar range; the isolated LKKTETQ heptapeptide binds far more weakly than the intact protein

  Sequesters actin monomers, buffering the polymerisable pool and permitting rapid cytoskeletal remodelling. This is an intracellular function, which is the central puzzle for an injected peptide.

• Integrin-linked kinase (ILK) / Akt — Not a direct binding interaction with a published constant

  Activation promotes cell survival and migration; this is the pathway identified in the cardiac repair work and the most plausible route for an extracellular effect.

• Endothelial angiogenic signalling — Not characterised

  Increased endothelial migration and tube formation, contributing to capillary ingrowth in injured tissue.

• Myofibroblast / TGF-beta driven fibrosis — Not characterised; partly attributable to the Ac-SDKP metabolite

  Reduced myofibroblast activation and less collagen scar in cardiac and dermal injury models - the basis for the scar-quality claims.

• No controlled human trial of TB-500 for tendon, ligament or muscle injury exists None

  This is the entry that matters. Every human trial in this space used full-length thymosin beta-4 in ophthalmic, dermal or cardiac indications. Nobody has ever run a controlled trial of the marketed TB-500 product for the musculoskeletal use that drives essentially all demand.

Week 1: nothing, other than possible lethargy for a day after each loading dose. This is expected and is the reason the loading phase exists. Weeks 2-4: the first window where most people report a change in the injury. Judge it with a fixed loading test, not by how the tissue feels on waking. Weeks 4-6: end of loading. This is the honest assessment point. If a repeatable test has not moved, moving to maintenance is unlikely to rescue it. Weeks 6-14: maintenance. Improvement here tends to be gradual and cumulative rather than stepwise. After stopping: no washout data exists. Anecdotally people describe the gains as holding, but there is no study behind that and no reason to expect a compound acting on cell migration to leave a lasting signal once the repair is finished.

TB-500 plus BPC-157 is the archetypal repair stack and the mechanisms genuinely complement rather than overlap. BPC-157 builds local blood supply daily and near the site; TB-500 works systemically and weekly on the ability of cells to migrate into that newly perfused tissue. If you are going to run two compounds for an injury, this is the pair with the most coherent rationale, even though neither has human efficacy data. With GHK-Cu the target is scar quality rather than healing speed, which is the right combination for dermal wounds and post-surgical incisions. With thymosin beta-4 proper, this is redundant - and frequently literally the same molecule, since much of what ships as TB-500 is the full-length peptide. Running both is duplication at double the price. One timing note worth having: because TB-500 dosing is weekly and BPC-157 dosing is daily, people frequently drift into taking their TB-500 shot 'whenever'. Fix the day. The whole premise of weekly dosing is that the tissue effect persists between doses, and irregular spacing makes the eight-week assessment uninterpretable.

Against BPC-157: different jobs. BPC-157 is local, daily, cheap and best for a single identified structure. TB-500 is systemic, weekly, more expensive, and better suited to multi-site or diffuse soft-tissue problems. TB-500 also carries the more serious theoretical malignancy concern of the two. Against full-length thymosin beta-4: often the same molecule, sold at different prices under different names. Thymosin beta-4 at least has real randomised human data in ophthalmology, so if you are buying anyway, buying the molecule that has actually been in a controlled trial is the more defensible choice. Against a properly progressive loading programme: no contest, and this needs saying. Tendon and muscle adapt to mechanical load. TB-500 has no human musculoskeletal trial at all. If you are choosing between paying for a peptide and paying for a competent rehab programme, the rehab is the one with the evidence.

$45–$150/month. Order-of-magnitude estimate at 5 mg per week during loading, dropping by half at maintenance. Not price-checked in the preparation of this entry, and heavily dependent on whether the vial contains the fragment or the full-length peptide.

• ?No pharmacokinetic parameter has ever been established for the marketed TB-500 product - no tmax, half-life, bioavailability, volume of distribution or clearance.
• ?The identity of the molecule sold as TB-500 is genuinely uncertain and varies between vendors, which is why the sequence verification flag is false.
• ?Whether the isolated LKKTETQ fragment reproduces the activity of full-length thymosin beta-4 has never been settled; the fragment binds actin far more weakly than the intact protein.
• ?The four-to-six week loading convention and 2-2.5 mg dose band come entirely from community practice, not from any dose-ranging study in any species at human-equivalent doses.
• ?How much of the antifibrotic effect belongs to thymosin beta-4 itself versus its Ac-SDKP metabolite is unresolved.
• ?The malignancy concern is inferred from expression-correlation studies in tumours, not from any study of exogenous administration. It is a real mechanistic worry with no direct evidence in either direction.
• ?Cost figures are estimates and were not price-verified in this session.

• Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair Bock-Marquette I, Saxena A, White MD, DiMaio JM, Srivastava D, Nature, 2004 · PMID 15565145

  The paper that moved thymosin beta-4 from 'actin buffer' to 'signalling molecule' by identifying the integrin-linked kinase and Akt pathway. The single most important mechanistic citation for this compound.

• Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial Sosne G, Ousler GW, Cornea, 2015 · PMID 25826322

  Real randomised human data for full-length thymosin beta-4 - but ophthalmic, not musculoskeletal. Included so the distinction is visible rather than blurred.